NeOnc Technologies (NTHI) announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer, CCO. Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational research, and academic medicine.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTHI:
- NeOnc Technologies files to sell 5.71M shares of common stock for holders
- NeOnc Technologies announces global patent portfolio totals 176
- NeOnc Technologies expects full enrollment in Phase 2a trial of NEO100-01
- NeOnc Technologies Appoints New President Amid Strategic Moves
- NeOnc Technologies appoints Heshmatpour as President